ClinicalTrials.gg
CompletedNCT01473108Updated Feb 9, 2022

Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862

A Phase 1 interventional study of Finerenone (BAY 94-8862) PEG solution and Finerenone (BAY 94-8862) immediate release tablet in Clinical Pharmacology, sponsored by Bayer. Completed at 1 site in Germany. Open to male participants aged 18 Years to 46 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-09.

Sponsored by Bayer · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Mar 2010, registered Aug 2011).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
18 Years to 46 Years
Sex
Male
01

Study summary

Pharmacodynamics, pharmacokinetics, safety, and tolerability will be investigated in this single dose study. In 5 treatment groups, different dosages of BAY94-8862 will be given in healthy male subjects.

Read the detailed description

Clinical pharmacology

02

Conditions studied

  • Clinical Pharmacology

Keywords

  • Healthy volunteers, proof-of-concept trial, PK and PD
03

In context

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 46 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male white subjects
  • 18 to 46 years of age
  • (BMI): 18 - 29.9 kg/m²

Exclusion criteria

Exclusion Criteria:

  • findings in medical history or in the physical examination
  • Systolic blood pressure below 100 or above 140 mmHg
  • Diastolic blood pressure below 50 or above 90 mmHg
  • Heart rate below 45 or above 95 beats / min
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    Finerenone (20 mg solution)

    3-fold crossover of single dose 20 mg BAY 94-8862 solution, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.

    Drug: Finerenone (BAY 94-8862) PEG solution · Drug: Eplerenone (Inspra®) · Drug: Placebo

  • Experimental
    Finerenone (10 mg solution)

    3-fold crossover of single dose 10 mg BAY 94-8862 solution, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.

    Drug: Finerenone (BAY 94-8862) PEG solution · Drug: Eplerenone (Inspra®) · Drug: Placebo

  • Experimental
    Finerenone (5 mg solution)

    3-fold crossover of single dose 5 mg BAY 94-8862 solution, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.

    Drug: Finerenone (BAY 94-8862) PEG solution · Drug: Eplerenone (Inspra®) · Drug: Placebo

  • Experimental
    Finerenone (20 mg as tablets)

    3-fold crossover of single dose 20 mg BAY 94-8862 as 2 x 10 mg tablet, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.

    Drug: Finerenone (BAY 94-8862) immediate release tablet · Drug: Eplerenone (Inspra®) · Drug: Placebo

  • Experimental
    Finerenone (2.5 mg solution)

    3-fold crossover of single dose 2.5 mg BAY 94-8862 solution, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.

    Drug: Finerenone (BAY 94-8862) PEG solution · Drug: Eplerenone (Inspra®) · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Log10 (10*urinary Na+/K+ ratio) (Parameter for natriuresis)

    Time frame: Up to 26 hours post-dose

  2. AUC (Area under the concentration vs time curve from zero to infinity after single (first) dose for both BAY 94-8862 and eplerenone)

    Time frame: Up to 60 hours after administration

  3. Cmax (Maximum observed drug concentration in measured matrix after single dose administration for both BAY 94-8862 and eplerenone)

    Time frame: Up to 60 hours after administration

Secondary outcomes

  1. Number of participants with adverse events

    Time frame: Up to 28 days

07

Study locations

1 site
  • Neuss, Nordrhein-Westfalen 41460, Germany
08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2010 to primary completion in Nov 2010, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2011
First posted
Nov 17, 2011
StartActual
Mar 29, 2010
Primary completionActual
Nov 30, 2010
CompletionActual
May 17, 2011
Last update
Feb 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01473108
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Nov 17, 2011
Start date
Mar 29, 2010
Primary completion
Nov 30, 2010
Completion
May 17, 2011
Last update
Feb 9, 2022

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Finerenone

Start the discussion